Testing the Addition of a New Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Conditions: Lymphoplasmacytic Lymphoma; Waldenstrom Macroglobulinemia Interventions: Drug: Ibrutinib; Biological: Rituximab; Drug: Venetoclax Sponsor: National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Lymphoma | Macroglobulinemia | Research | Rituxan | Waldenstrom's Macroglobulinemia